As well as the overexpression of ERBB proteins following ALK-TKI treatment in EML4-ALK-rearranged NSCLC cells, we also identified high levels of AKT1 and PI3K activities upon LOR treatment. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.